Physician profile
Macy E Saunders
NPI 1639793094
$29,540.78
in general payments reported to CMS, 2019-2025
18 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $433 · 2023: $472 · 2024: $4,408 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,831 · Travel and Lodging: $4,849 · Food and Beverage: $3,770 · Honoraria: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,700.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,830.94 |
| Travel and Lodging | $4,849.15 |
| Food and Beverage | $3,769.94 |
| Honoraria | $812.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $20,598.88 | 2021-2025 | |
| Organon LLC | $7,879.91 | 2021-2025 | Nexplanon |
| Abiomed | $148.62 | 2025 | |
| Abbvie INC. | $142.00 | 2021-2022 | |
| Scynexis, INC. | $120.25 | 2022 | |
| Pfizer INC. | $118.99 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $117.31 | 2023 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $105.65 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $58.69 | 2022 | |
| Exact Sciences Corporation | $50.17 | 2023-2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $44.52 | 2022-2023 | Accrufer |
| Exeltis, USA INC. | $42.03 | 2023-2024 | Slynd |
| Merck Sharp & Dohme LLC | $29.50 | 2023 | Gardasil 9 |
| Coopersurgical, INC. | $19.81 | 2024 | Paragard T 380a |
| Astellas Pharma US INC | $19.13 | 2023 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.91 | 2025 | Ozempic |
| Evofem Biosciences, INC. | $15.03 | 2022 | |
| Avion Pharmaceuticals | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macy Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.